Glaxosmithkline, Bristol-Myers Squibb, and Aids in Africa

†¢ Case – 2 Marks-20In 2004, the United Nations estimated that the previous year 5 million more people around the world hadcontracted the AIDS virus, 3 million had died, and a total of 40 million people were living with theinfection. Seventy percent, or about 28 million of these, lived in sub – Saharan Africa, where the epidemicwas at its worst. Sub – Saharan Africa consists of the 48 countries and 643 million people who residesouth of the Saharan desert. In 16 of these countries, 10 percent are infected with the virus, in 6 othernation, 20 percent are infected. The UN predicted that in these 6 nations two – thirds of all 15 – year oldswould eventually die of AIDS and in those where 10 percent were infected, half of all 15 – year –†¦show more content†¦In1987, Burroughs Wellcome (now part of GlaxoSmithKline) developed AZT, the first FDA-approvedantiretroviral, that is, a drug that attacks the HIV virus itself. When wellc ome priced AZT at $10,000 for ayear’s supply, it was accused of price gouging, forcing a price reducing of 20 percent the following year. In1991, Bristol- Myers Squibb developed didanosine, a new class of antiretroviral drug called nucleosidereverse transcriptase inhibitors. In 1995, Roche developed saquinavir, a third new class of antiretroviraldrug called a protease inhibitor, and the following year Roxane Laboratories announced nevirapine,another new class of antiretrovirals called nonnucleoside reverse transcriptase inhibitors . By the middle1990s, drug companies had developed four distinct classes of antiretrovirals, as several drugs thatattacked the opportunistic diseases that afflict AIDS patients. In 1996, Dr. David Ho was honored for his discovery that by taking a combination- a â€Å"cocktail†- ofthree of than four classes of antiretroviral drags, it is possible to kill off virtually all of than HIV virus in apatient’s body, allowing the immune system to recover, and thereby effectively bringing the disease intoremission. Costing upwards of $20,000 a year (the medicines had to be taken for the rest of the patient’slife), the new drug treatment enabled AIDS patients to once again live normal, healthy lives. By 1998, thelarge drug companies wouldShow MoreRelatedCompany Ethics and Moral1176 Words   |  5 Pagesdisease, diabetes, hepatitis, Parkinson’s, HIV/AIDS and some cancers (Dowdall, 2014). Without several of these drugs that are provided by these companies, many people would not live healthier longer lives. â€Å"Malaria, a mosquito-borne parasitic disease, kills hundreds of thousands of people a year, mainly babies in the poorest parts of sub-Saharan Africa, and scientists say an effective vaccine is key to attempts to eradicate it† (Moorthy, 2013). GlaxoSmithKline, a British drug maker has created the worldsRead MorePharma Industry Analysis1714 Words   |  7 PagesGood health is an important personal and social requirement and the unique role pharmaceutical firms play in meeting society’s need for popular wellbeing cannot be underestimated. In recent times, the impact of various global epidemics e.g. SARS, AIDS etc has also attracted popular and media attention to the industry. The effect of the intense media and political attention has resulted in increasing industry efforts to create and maintain good government-industry-society communications. TechnologicalRead MorePfizer Tested A New Antibiotic1483 Words   |  6 Pagestiming of antiretroviral treatment for HIV positive people is taking place in the African countries of Morocco, Mali, Nigeria, South Africa, and Uganda (â€Å"Strategic Timing†). The Strategic Timing of Antiretrovial Treatment (START) study is currently sponsored by the University of Minnesota and has twenty-one collaborators including GlaxoSmithKline, Bristol-Myers Squibb and Merck. The study s objective is to assess the mortality rate of HIV patients over the course of four years. Numerous antiretroviralRead MoreEthical Justification For Providing Life Saving Medicines2109 Words   |  9 Pagesshareholders of the company, especially in recouping the money that has been spent on the research. If a company does patent its HIV/AIDS drug then they protect it from being common knowledge and avoid losing an edge over other companies, not to mention the millions or billions in profits. Today, approxima tely 35 million people in the world are currently living with the HIV/AIDS disease (13), which leads us to the question: Should pharmaceutical companies be forced to make drug advancements public knowledgeRead MoreGsk Marketing Planning4419 Words   |  18 PagesGSK Marketing Planning | March 31 2013 | Calvin Cheung, Hussain Al Katib, Manpreet Budwal, Sandra Okechukwu | SOSTAC Review based on GlaxoSmithKline | Content Table of Contents 1.0 Introduction2 2.0 Situation Analysis3 2.1 PESTEL Analysis3 2.2 SWOT Analysis4 2.3 Boston Matrix5 2.4 Porter’s Five Forces Analysis6 3.0 Objectives8 4.0 Strategy9 4.1 Product9 4.2 Price9 4.3 Promotion9 4.4 Place10 4.5 Person10 4.6 Process10 4.7 Physical Evidence10 5.0 Tactics11 6.0 Action Plan12 Read MoreHistory and Analysis of the Pharmaceutical Industry4211 Words   |  17 PagesGood health is an important personal and social requirement and the unique role pharmaceutical firms play in meeting society’s need for popular wellbeing cannot be underestimated. In recent times, the impact of various global epidemics e.g. SARS, AIDS etc has also attracted popular and media attention to the industry. The effect of the intense media and political attention has resulted in increasing industry efforts to create and maintain good government-industry-society communications. TechnologicalRead MoreGlaxosmithkline18561 Words   |  75 PagesGlaxoSmithKline company profile Francis Weyzig Amsterdam, October 2004 Summary Business description GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. Headquarters: UK, with additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figuresRead MoreMergers Acquisitions in Pharma Industry21425 Words   |  86 PagesPROJECT REPORT ON A Successful International Merger in India: GlaxoSmithKline pharmaceutical industry Table of Contents: Declaration Abstract Part I –Introduction Research Objective and justifications Report Outline Part-II Industry DescriptionRead MoreProblems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability14741 Words   |  59 Pagesconsumer 3 products, healthcare services, medical devices and medical diagnostics. Yet other companies have taken the path of focusing on the Emerging Markets that are in some ways considered largely untapped potential like AstraZeneca and GlaxoSmithKline s focus on China and India respectively. These are examples of changes that point to the fact that many Pharma companies do not see the current situation as a temporary setback. Many are making the decision to work with former competitors (EliRead MoreGsk Annual Report 2010135604 Words   |  543 PagesDo more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Governance and remuneration P58–P101 Financial statements P102–P191 Shareholder information P192–P212 Business review 2010 Performance overview Research and development Pipeline summary Products, competition and intellectual property Regulation Manufacturing and supply World market GSK sales performance Segment reviews Responsible business Financial review 2010 Financial position and resources